Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Medanta expanded its bed capacity by 20% during the year
Medanta expanded its bed capacity by 20% during the year
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Subscribe To Our Newsletter & Stay Updated